Papulopustular Rosacea
Conditions
Brief summary
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT). The objective of this study is twofold: 1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea. 2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.
Interventions
DRUGRifaximin
Rifaximin tablets
DRUGPlacebo
Placebo tablets
Sponsors
bioRASI, LLC
Alfasigma S.p.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Men and women aged 18 years or older at screening. * Female participants are eligible if they are: i) of non-childbearing potential or ii) of childbearing potential with a negative pregnancy test result at screening and randomization AND agreeing to use a highly effective method of contraception until 72 hours after taking the last study treatment dose. * Presence of rosacea, papulopustular phenotype. * Presence of ≥11 and ≤70 facial papules and/or pustules. * Moderate or severe rosacea based on Investigator's Global Assessment based on Investigator's judgement. * Patients accepting to provide and legally capable of providing free and informed consent to all procedures included in the protocol (including the availability to perform a Lactulose Breath Test). Main
Exclusion criteria
* Granulomatous rosacea or rosacea fulminans. * Erythematotelangiectatic, phymatous or ocular rosacea only. Patients with these subtypes associated with papulopustular rosacea can be enrolled. * Rosacea with Investigator's Global Assessment (IGA) grade ≤2 based on Investigator's judgment. * Anticipated need for proctoscopy or colonoscopy within two weeks after lactulose breath test. * Subjects requiring a low galactose diet. * Hypersensitivity or intolerance to lactulose or any excipient of the lactulose reparation to be used for L-BT. * History of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other conditions characterized by severe intestinal ulcers. * History of coeliac disease. * Patients with intestinal obstruction or partial intestinal obstruction. * Presence of diarrhoea associated with fever and/or blood in the stool. * Severe kidney impairment (i.e. estimated glomerular filtration rate \<30 ml/min). * Severe hepatic impairment (i.e. Child-Pugh B or C). * Cancer or any cancer-related treatment within 5 years prior to screening (excluding non-melanoma skin-cancer). * History of alcohol or drug abuse within a year prior to screening, based on Investigator's judgement. * Facial skin conditions that can interfere with reliable assessment of rosacea throughout the study (e.g. facial hair, tattoos, other facial adornments, keloids, hypertrophic scarring, recent facial surgery, excessive sun exposure including use of tanning beds) * Any other significant health condition (e.g. cardiovascular, respiratory, renal, hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) or non-health condition that in the investigator's judgement may: i) jeopardize the patient's safe participation in the trial or ii) make unlikely the patient's completion of the study or iii) make unlikely the patient's compliance with the study procedures (e.g. highly anticipated need of non-permitted treatments, terminal illness, etc.). * History of hypersensitivity to the study drug. * Treatment with biologic immunomodulatory and/or immunosuppressive drugs (e.g. anti-tumor necrosis factor \[TNF\] drugs) within 6 months prior to randomization. * Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g. cyclosporine, methotrexate etc.) within 30 days prior to randomization. * Treatment with warfarin (or other coumarins) within 14 days prior to randomization. * Treatment with niacin within 30 days prior to randomization. * Topical facial or systemic antibiotics within 30 days before randomization; * Treatment with neomycin or other low-absorbable oral antibiotics within 90 days before randomization. * Topical facial, inhaled or systemic corticosteroids within 30 days prior to randomization. * Topical facial retinoids within 30 days before randomization. * Systemic retinoids within 6 months before randomization. * Any other topical or systemic treatment for rosacea within 30 days before randomization (including also laser and pulsed light, etc.). * Over-the-counter intestinal or topical skin probiotics (functional food is allowed), within 30 days before randomization. * Any experimental treatment within 6 months prior to randomization. * Current swab-positive or suspected (under investigation) Covid-19 infection; or fever and one or more of the following respiratory disease signs or symptoms: cough, sputum production, shortness of breath within the last 14 days; or contact with people with Covid-19 infection within the last 14 days. * Women who are pregnant, breast-feeding or planning a pregnancy during the trial period. * Subjects who are investigational site staff members and their family members, site staff members otherwise supervised by the investigator, or patients who are Alfasigma's employees.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions | 30 days | This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment. |
| Co-primary Endpoint: Treatment Success Rate | 30 days | This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Rifaximin 250 mg TID 1 tablet of Rifaximin 250 TID (750 mg daily) + 1 tablet of placebo TID | 65 |
| Rifaximin 500 mg TID 2 tablets of Rifaximin 250 mg TID (1500 mg daily) | 76 |
| Placebo 2 tablets of placebo TID | 63 |
| Total | 204 |
Baseline characteristics
| Characteristic | Placebo | Total | Rifaximin 250 mg TID | Rifaximin 500 mg TID |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 9 Participants | 25 Participants | 7 Participants | 9 Participants |
| Age, Categorical Between 18 and 65 years | 54 Participants | 179 Participants | 58 Participants | 67 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 12 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 2 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 5 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) White | 56 Participants | 183 Participants | 59 Participants | 68 Participants |
| Sex: Female, Male Female | 44 Participants | 150 Participants | 52 Participants | 54 Participants |
| Sex: Female, Male Male | 19 Participants | 54 Participants | 13 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 70 | 0 / 80 | 0 / 66 |
| other Total, other adverse events | 8 / 70 | 17 / 80 | 12 / 66 |
| serious Total, serious adverse events | 0 / 70 | 0 / 80 | 0 / 66 |
Outcome results
Primary
Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions
This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment.
Time frame: 30 days
Population: The primary efficacy outcomes measures are reported on the Full Analysis Set
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rifaximin 250 mg TID | Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions | -10.0 lesions (rosacea inflammatory) | Standard Deviation 9.24 |
| Rifaximin 500 mg TID | Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions | -6.7 lesions (rosacea inflammatory) | Standard Deviation 14.78 |
| Placebo | Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions | -9.2 lesions (rosacea inflammatory) | Standard Deviation 10.49 |
Primary
Co-primary Endpoint: Treatment Success Rate
This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment.
Time frame: 30 days
Population: The primary efficacy outcomes measures are reported on the Full Analysis Set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rifaximin 250 mg TID | Co-primary Endpoint: Treatment Success Rate | 9.23 Percentage of participants |
| Rifaximin 500 mg TID | Co-primary Endpoint: Treatment Success Rate | 9.21 Percentage of participants |
| Placebo | Co-primary Endpoint: Treatment Success Rate | 11.11 Percentage of participants |